4.7 Article

Association of Door-In to Door-Out Time With Reperfusion Delays and Outcomes Among Patients Transferred for Primary Percutaneous Coronary Intervention

Journal

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 305, Issue 24, Pages 2540-2547

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2011.862

Keywords

-

Funding

  1. Bristol-Myers Squibb/Sanofi
  2. Schering Plough/Merck
  3. Medicines Co
  4. Heartscape
  5. Canyon Pharmaceuticals
  6. Eli Lilly/Daiichi Sankyo Alliance
  7. Eli Lilly
  8. Novartis
  9. Merck-Schering Plough
  10. Bristol-Myers Squibb
  11. American College of Cardiology
  12. American Heart Association
  13. Glaxo Smith Kline
  14. KAI Pharmaceuticals
  15. Sanofi-Aventis
  16. Orexigen
  17. Astra Zeneca
  18. St Jude Inc
  19. Bayer
  20. Pfizer
  21. ACC Foundation's NCDR
  22. Society of Chest Pain Centers
  23. American College of Emergency Physicians
  24. Society of Hospital Medicine

Ask authors/readers for more resources

Context Patients with ST-elevation myocardial infarction (STEMI) requiring inter-hospital transfer for primary percutaneous coronary intervention (PCI) often have prolonged overall door-to-balloon (DTB) times from first hospital presentation to second hospital PCI. Door-in to door-out (DIDO) time, defined as the duration of time from arrival to discharge at the first or STEMI referral hospital, is a new clinical performance measure, and a DIDO time of 30 minutes or less is recommended to expedite reperfusion care. Objective To characterize time to reperfusion and patient outcomes associated with a DIDO time of 30 minutes or less. Design, Setting, and Patients Retrospective cohort of 14 821 patients with STEMI transferred to 298 STEMI receiving centers for primary PCI in the ACTION Registry-Get With the Guidelines between January 2007 and March 2010. Main Outcome Measures Factors associated with a DIDO time greater than 30 minutes, overall DTB times, and risk-adjusted in-hospital mortality. Results Median DIDO time was 68 minutes (interquartile range, 43-120 minutes), and only 1627 patients (11%) had DIDO times of 30 minutes or less. Significant factors associated with a DIDO time greater than 30 minutes included older age, female sex, off-hours presentation, and non-emergency medical services transport to the first hospital. Patients with a DIDO time of 30 minutes or less were significantly more likely to have an overall DTB time of 90 minutes or less compared with patients with DIDO times greater than 30 minutes (60% [95% confidence interval {CI}, 57%-62%] vs 13% [95% CI, 12%-13%]; P < .001). Among patients with DIDO times greater than 30 minutes, only 0.6% (95% CI, 0.5%-0.8%) had an absolute contraindication to fibrinolysis. Observed in-hospital mortality was significantly higher among patients with DIDO times greater than 30 minutes vs patients with DIDO times of 30 minutes or less (5.9% [95% CI, 5.5%-6.3%] vs 2.7% [95% CI, 1.9%-3.5%]; P < .001; adjusted odds ratio for in-hospital mortality, 1.56 [95% CI, 1.15-2.12]). Conclusion A DIDO time of 30 minutes or less was observed in only a small proportion of patients transferred for primary PCI but was associated with shorter reperfusion delays and lower in-hospital mortality. JAMA. 2011;305(24):2540-2547

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available